Impact of Second-Line Combination Treatment for Type 2 Diabetes Mellitus on Disease Control: A Population-Based Cohort Study.

Dan OuchiCarles Vilaplana-CarnereroRamon MonfàMaria Giner-SorianoAna Garcia-SangenísFerran TorresRosa Morros

Published in: Drugs - real world outcomes (2023)

Patients achieved the glycated hemoglobin goal with second-line treatments. Glucagon-like peptide-1 and insulin combinations achieved the goal earlier than sulfonylurea combinations. Adherence significantly reduced the time to glycated hemoglobin control except for the combination with sodium-glucose cotransporter type 2 inhibitors.

Keyphrases

end stage renal disease
glycemic control
ejection fraction
type diabetes
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes
metabolic syndrome
cardiovascular disease
adipose tissue
cardiovascular risk factors
insulin resistance
patient reported